Shriner's Burn Hospital closed the study and access to study-related data is unavailable. We are unable to submit the additional information or results-data

The proposed study will test the hypothesis that Propranolol, fenofibrate and fenofibrate plus propranolol have therapeutic, physiological, and metabolic effects that will improve clinical outcomes, and the long-term recovery, rehabilitation, and QOL in burned patients.

Determine the clinical benefits and underlying mechanisms whereby the metabolic perturbators fenofibrate and propranolol impact burn patient outcomes. The investigators hypothesize that these metabolic regulators given for one year will maintain body mass, improve muscle function by increasing protein synthesis, augment wound healing, reduce fibrosis, improve cardiovascular function, reduce systemic inflammation, restore insulin sensitivity, and decrease liver dysfunction without the risk of the hypoglycemia.

Inclusion Criteria:

• 0 through 80 years
• ≥ 20% Total Body Surface Area Burn injury

Exclusion Criteria:

Pregnancy

History or existence of pre-burn injury conditions

• Allergies to propranolol or fenofibrate
• Asthma requiring treatment
• Congestive heart failure (measured ejection fraction < 20%)
• Renal or hepatic disease
• Medical condition requiring glucocorticoid treatment
• History of AIDS, Aids Related Complex or HIV
• History of Cancer within 5 years

Decision not to treat due to burn injury severity or futility as deemed by the clinical team